|
Mental deterioration
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
APOE epsilon4 was significantly and uniquely related to lower score at baseline and significantly increased the odds of cognitive decline by 59%.
|
11559372 |
2001 |
|
Mental deterioration
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
APOE-epsilon4 is associated with cognitive decline among a high-functioning elderly cohort, with effects most pronounced after 7 years of follow-up.
|
12682309 |
2003 |
|
Mental deterioration
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging.
|
15365129 |
2004 |
|
Mental deterioration
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
APOE epsilon4 is associated with greater cognitive decline in middle-aged Caucasian individuals, with a reduced decline among epsilon2 carriers.
|
15668424 |
2005 |
|
Mental deterioration
|
0.200 |
GeneticVariation
|
phenotype |
BEFREE |
Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementia.
|
16389198 |
2006 |
|
Mental deterioration
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
Apolipoprotein E (APOE) is the major genetic risk factor for late-onset Alzheimer's disease (AD) and has also been implicated in cardiovascular disease, cognitive decline and cognitive changes in healthy ageing.
|
17911980 |
2007 |
|
Mental deterioration
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
APOE epsilon 4 may influence rate of cognitive decline most significantly in the earliest stages of Alzheimer disease.
|
18401023 |
2008 |
|
Mental deterioration
|
0.200 |
GeneticVariation
|
phenotype |
BEFREE |
APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study.
|
19321880 |
2009 |
|
Mental deterioration
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
APOE4 carriers with cognitive decline undergo faster GM atrophy than do noncarriers.
|
21163916 |
2011 |
|
Mental deterioration
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
APOE ε4 status alone significantly predicted cognitive decline (R(2) = .106; C index = .642).
|
23199565 |
2013 |
|
Mental deterioration
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
Apolipoprotein E (ApoE) is the most well-described genetic risk factor for Alzheimer's disease and nonpathological cognitive decline.
|
24261350 |
2015 |
|
Mental deterioration
|
0.200 |
GeneticVariation
|
phenotype |
BEFREE |
APOE ε4 allele(s) may be a useful genetic marker to identify white and mixed-race HIV subjects at risk for cognitive decline.
|
24850492 |
2014 |
|
Mental deterioration
|
0.200 |
GeneticVariation
|
phenotype |
BEFREE |
APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease.
|
25288138 |
2015 |
|
Mental deterioration
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
APOE genotype, along with other biomarkers, may be used in the future to assist nurses in identifying women with breast cancer most at risk for cognitive decline.
|
25355028 |
2014 |
|
Mental deterioration
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
APOE ε4 and the associations of seafood and long-chain omega-3 fatty acids with cognitive decline.
|
27164694 |
2016 |
|
Mental deterioration
|
0.200 |
GeneticVariation
|
phenotype |
BEFREE |
APOE ϵ4 genotype accelerated cognitive decline in HIV(+) but not HIV(-) men (P = .01), with trajectories diverging from HIV(-) ε4 carriers after age 50.
|
27448678 |
2016 |
|
Mental deterioration
|
0.200 |
GeneticVariation
|
phenotype |
BEFREE |
Apolipoprotein E (APOE) e4 allele carriers had greater cognitive decline per unit of CPF.
|
27467026 |
2017 |
|
Mental deterioration
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
ApoE4/BMI category analyses demonstrated lower Aβ load, higher posterior cingulate glucose metabolism, improved cognitive performance, and lower progression of cognitive decline in obese ApoE4 carriers.
|
28697560 |
2018 |
|
Mental deterioration
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.
|
29168904 |
2018 |
|
Mental deterioration
|
0.200 |
GeneticVariation
|
phenotype |
BEFREE |
Apolipoprotein E e4 Allele Is Associated with Subjective Cognitive Decline: A Meta-Analysis.
|
29169179 |
2017 |
|
Mental deterioration
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
Apolipoprotein-E (Apoe) ε4 and cognitive decline over the adult life course.
|
29317609 |
2018 |
|
Mental deterioration
|
0.200 |
GeneticVariation
|
phenotype |
BEFREE |
APOEɛ4 carriers with high AD-GRS are at elevated risk of cognitive decline when they also possess higher CA-GRS risk.
|
29480189 |
2018 |
|
Mental deterioration
|
0.200 |
GeneticVariation
|
phenotype |
BEFREE |
Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample.
|
7475820 |
1995 |
|
Mental deterioration
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
Apolipoprotein E epsilon 4 is associated with cognitive decline in community-dwelling nondemented women.
|
9311354 |
1997 |
|
Mental deterioration
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
APOE-epsilon4 homozygosity is associated with a faster rate of cognitive decline, whereas the epsilon2 allele slows disease progression.
|
9674794 |
1998 |